Welcome to our dedicated page for Oculis Holding news (Ticker: OCS), a resource for investors and traders seeking the latest updates and insights on Oculis Holding stock.
Oculis Holding AG (OCS) generates a steady flow of news related to its late-stage biopharmaceutical pipeline in ophthalmology and neuro-ophthalmology. Company announcements highlight clinical trial milestones, regulatory designations, capital markets activity, and scientific presentations that are relevant for investors and observers tracking developments in optic neuropathies and retinal disease.
Recent news releases describe the advancement of Privosegtor, a peptoid small-molecule neuroprotective candidate, into the PIONEER registrational program for optic neuritis and non-arteritic anterior ischemic optic neuropathy. Oculis has reported positive Phase 2 ACUITY data in acute optic neuritis and disclosed that Privosegtor has received Breakthrough Therapy designation from the U.S. FDA and Orphan Drug designation from the FDA and EMA. Updates often cover trial design, endpoints such as low-contrast visual acuity, and planned global enrollment.
News coverage also follows OCS-01 eye drops in Phase 3 DIAMOND studies for diabetic macular edema, including the use of the company’s OPTIREACH technology to deliver dexamethasone topically to the retina. In addition, Oculis issues releases on Licaminlimab for dry eye disease, participation in major medical meetings such as the J.P. Morgan Healthcare Conference and ophthalmology congresses, and insider transaction notifications related to restricted stock unit vesting and director share purchases.
For readers monitoring OCS, this news feed provides company-sourced updates on clinical progress, regulatory interactions, financing transactions disclosed in Form 6-K filings, and scientific data presentations. It can be a useful reference for following how Oculis advances its investigational therapies for optic neuritis, NAION, diabetic macular edema, and dry eye disease over time.
Oculis (OCS) announced notifications of transactions by persons discharging managerial responsibilities related to the vesting and settlement of RSUs previously granted to company directors.
Named directors with RSU vesting notifications include Riad Sherif (6 March 2026), Robert Warner (4 March 2026), Arshad Khanani (4 and 6 March 2026), Christina Ackermann (4 March 2026) and Anthony Rosenberg (4 March 2026).
Oculis (NASDAQ: OCS) announced that it has filed its audited consolidated IFRS financial statements for the 2025 fiscal year and the MD&A on Form 20-F with the SEC on March 5, 2026. Attachments include the 2025 consolidated financial statements, the MD&A and ESEF reporting files.
Oculis (Nasdaq: OCS) announced management participation in investor conferences in March 2026, presenting updates on its late-stage ophthalmology and neuro-ophthalmology pipeline.
Highlights include breakthrough therapy designation for Privosegtor in optic neuritis, DIAMOND Phase 3 topline timing for OCS-01 in Q2 2026, and the PREDICT-1 licaminlimab program.
Oculis (OCS) published a notification on March 4, 2026 regarding the vesting and settlement of restricted stock units (RSUs) previously granted to a director. The disclosure names Arshad Khanani and references an RSU vesting event dated 28 February 2026.
Oculis (Nasdaq: OCS) reported strong 2025 progress with CHF 213.0M ($268.7M) cash and short-term investments as of Dec 31, 2025, providing a runway into 2029. Key clinical milestones: DIAMOND Phase 3 topline for OCS-01 expected Q2 2026; FDA Breakthrough Therapy granted for Privosegtor; PIONEER and PREDICT-1 registrational programs launched.
Financials: 2025 net loss CHF 98.96M ($119.1M); increased R&D and G&A driven by late-stage trials; 2.0M new treasury shares issued under ATM program.
Oculis (NASDAQ:OCS) disclosed a notification under managers' transactions relating to the vesting and settlement of RSUs previously granted to director Arshad Khanani. The notification references an RSU vest on 25 February 2026 and was published on 27 February 2026.
Oculis (OCS) notified investors on Feb 18, 2026 that certain managerial transactions relate to the vesting of earnout shares and the associated removal of restrictions on those ordinary shares.
The notifications name four managers: Anthony Rosenberg, Pall Johannesson, Riad Sherif, and Sylvia Cheung.
Oculis (Nasdaq: OCS) appointed Katie Kazem as Chief Legal Officer on Feb 17, 2026, to lead legal, compliance, and corporate governance functions.
Ms. Kazem brings 15+ years of capital markets and life‑sciences legal experience and has advised Oculis since its NASDAQ listing in March 2023. The move coincides with Privosegtor entering the PIONEER registrational program and DIAMOND Phase 3 topline results expected in Q2 2026.
Oculis (Nasdaq: OCS) said it will present its late-stage ophthalmology and neuro-ophthalmology pipeline at the 2026 J.P. Morgan Healthcare Conference on Jan 14, 2026.
The company highlighted Privosegtor, granted breakthrough therapy designation for optic neuritis after ACUITY Phase 2 showed a mean +18 ETDRS letters at three months versus placebo, and announced the global PIONEER registrational program (PIONEER-1 started in Q4 2025). Oculis also expects DIAMOND Phase 3 topline results for OCS-01 in DME in Q2 2026 and plans an NDA submission in Q4 2026.
Oculis (Nasdaq: OCS) announced the U.S. FDA granted Breakthrough Therapy Designation to Privosegtor for treatment of optic neuritis on January 6, 2026. The designation is supported by Phase 2 ACUITY data showing an average +18‑letter gain in Low Contrast Visual Acuity (LCVA) at month 3 versus IV steroid alone, plus anatomical preservation and reduced neurofilament release. Oculis launched the registrational PIONEER program after a 2025 FDA meeting; PIONEER includes three pivotal trials and PIONEER‑1 in optic neuritis was initiated in Q4 2025 with global site activation and enrollment expected to begin shortly. The company cites a U.S. market opportunity of $7 billion for key optic neuropathies.